Clinical Trial

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving teclistamab may be safe and tolerable in treating patients with recurrent or refractory plasmablastic lymphoma.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-17
notable Primary completion pushed: 2027-02-28 -> 2027-12-31 2026-07-17
minor Completion pushed: 2027-02-28 -> 2027-12-31 2026-07-17
Trial Details
NCT Number NCT07332507
Lead Sponsor National Cancer Institute (NCI)
Conditions Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
Enrollment 30 participants
Start Date 2027-03-26
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11